<SEC-DOCUMENT>0000950170-25-002557.txt : 20250107
<SEC-HEADER>0000950170-25-002557.hdr.sgml : 20250107
<ACCEPTANCE-DATETIME>20250107074512
ACCESSION NUMBER:		0000950170-25-002557
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250107

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Astria Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001454789
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-88910
		FILM NUMBER:		25513478

	BUSINESS ADDRESS:	
		STREET 1:		22 BOSTON WHARF ROAD
		STREET 2:		10TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		617-349-1971

	MAIL ADDRESS:	
		STREET 1:		22 BOSTON WHARF ROAD
		STREET 2:		10TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CATABASIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20090127

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ForGrowth III PA B.V.
		CENTRAL INDEX KEY:			0002050902
		ORGANIZATION NAME:           	
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		FORBION CAPITAL PARTNERS
		STREET 2:		GOOIMEER 2-35
		CITY:			NAARDEN
		STATE:			P7
		ZIP:			1411
		BUSINESS PHONE:		31 356993000

	MAIL ADDRESS:	
		STREET 1:		FORBION CAPITAL PARTNERS
		STREET 2:		GOOIMEER 2-35
		CITY:			NAARDEN
		STATE:			P7
		ZIP:			1411
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<headerData>
<submissionType>SCHEDULE 13G</submissionType>
<filerInfo>
<filer>
<filerCredentials>
<cik>0002050902</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>
</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<securitiesClassTitle>Common Stock, $0.001 par value per share</securitiesClassTitle>
<eventDateRequiresFilingThisStatement>12/30/2024</eventDateRequiresFilingThisStatement>
<issuerInfo>
<issuerCik>0001454789</issuerCik>
<issuerName>Astria Therapeutics, Inc.</issuerName>
<issuerCusip>04635X102</issuerCusip>
<issuerPrincipalExecutiveOfficeAddress>
<street1 xmlns="http://www.sec.gov/edgar/common">22 Boston Wharf Road</street1>
<street2 xmlns="http://www.sec.gov/edgar/common">10th Floor</street2>
<city xmlns="http://www.sec.gov/edgar/common">Boston</city>
<stateOrCountry xmlns="http://www.sec.gov/edgar/common">MA</stateOrCountry>
<zipCode xmlns="http://www.sec.gov/edgar/common">02110</zipCode>
</issuerPrincipalExecutiveOfficeAddress>
</issuerInfo>
<designateRulesPursuantThisScheduleFiled>
<designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
</designateRulesPursuantThisScheduleFiled>
</coverPageHeader>
<coverPageHeaderReportingPersonDetails>
<reportingPersonName>ForGrowth III PA B.V.</reportingPersonName>
<memberGroup>b</memberGroup>
<citizenshipOrOrganization>P7</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>2872537</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>2872537</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2872537</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>5.1</classPercent>
<typeOfReportingPerson>OO</typeOfReportingPerson>
<comments>Based on 56,434,219 shares of Common Stock outstanding as of October 31, 2024, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2024.</comments>
</coverPageHeaderReportingPersonDetails>
<coverPageHeaderReportingPersonDetails>
<reportingPersonName>Forbion Growth Opportunities Fund III Cooperatief U.A.</reportingPersonName>
<memberGroup>b</memberGroup>
<citizenshipOrOrganization>P7</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>2872537</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>2872537</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2872537</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>5.1</classPercent>
<typeOfReportingPerson>OO</typeOfReportingPerson>
<comments>Based on 56,434,219 shares of Common Stock outstanding as of October 31, 2024, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2024.</comments>
</coverPageHeaderReportingPersonDetails>
<coverPageHeaderReportingPersonDetails>
<reportingPersonName>Forbion Growth III Management B.V.</reportingPersonName>
<memberGroup>b</memberGroup>
<citizenshipOrOrganization>P7</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>2872537</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>2872537</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2872537</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>5.1</classPercent>
<typeOfReportingPerson>OO</typeOfReportingPerson>
<comments>Based on 56,434,219 shares of Common Stock outstanding as of October 31, 2024, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2024.</comments>
</coverPageHeaderReportingPersonDetails>
<items>
<item1>
<issuerName>Astria Therapeutics, Inc.</issuerName>
<issuerPrincipalExecutiveOfficeAddress>22 Boston Wharf Road, 10th Floor, Boston, MA 02110</issuerPrincipalExecutiveOfficeAddress>
</item1>
<item2>
<filingPersonName>This statement is being filed by ForGrowth III PA B.V. ("ForGrowth III"), Forbion Growth Opportunities Fund III Cooperatief U.A. ("Forbion Growth III COOP") and Forbion Growth III Management B.V. ("Forbion Growth III"). ForGrowth III, Forbion Growth III COOP and Forbion Growth III are sometimes referred to collectively as the "Reporting Persons".</filingPersonName>
<principalBusinessOfficeOrResidenceAddress>The address of the principal business and principal office of each of the Reporting Persons is c/o Forbion Capital Partners, Gooimeer 2-35, 1411 DC Naarden, The Netherlands.</principalBusinessOfficeOrResidenceAddress>
<citizenship>Each of the Reporting Persons is organized under the laws of the Netherlands.</citizenship>
</item2>
<item3>
<notApplicableFlag>Y</notApplicableFlag>
</item3>
<item4>
<amountBeneficiallyOwned>ForGrowth III directly owns 2,872,537 shares of Common Stock. Forbion Growth III COOP, the sole shareholder of ForGrowth III, and Forbion Growth III, as director of each of ForGrowth III and Forbion Growth III COOP, may be deemed to have voting and investment power over the shares held directly by ForGrowth III.
</amountBeneficiallyOwned>
<classPercent>The shares of Common Stock beneficially owned by the Reporting Persons represent approximately 5.1% of the outstanding shares of Common Stock of the Issuer, based on 56,434,219 shares of Common Stock outstanding as of October 31, 2024, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2024.</classPercent>
<numberOfSharesPersonHas>
<solePowerOrDirectToVote>0</solePowerOrDirectToVote>
<sharedPowerOrDirectToVote>2,872,537</sharedPowerOrDirectToVote>
<solePowerOrDirectToDispose>0</solePowerOrDirectToDispose>
<sharedPowerOrDirectToDispose>2,872,537</sharedPowerOrDirectToDispose>
</numberOfSharesPersonHas>
</item4>
<item5>
<notApplicableFlag>Y</notApplicableFlag>
</item5>
<item6>
<notApplicableFlag>Y</notApplicableFlag>
</item6>
<item7>
<notApplicableFlag>Y</notApplicableFlag>
</item7>
<item8>
<notApplicableFlag>N</notApplicableFlag>
<identificationAndClassificationOfGroupMembers>The Reporting Persons are making this single, joint filing because they may be deemed to constitute a "group" within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Persons disclaim membership in a group and this report shall not be deemed an admission by any of the Reporting Persons that they are or may be members of a "group" for purposes of Rule 13d-5 or for any other purpose.</identificationAndClassificationOfGroupMembers>
</item8>
<item9>
<notApplicableFlag>Y</notApplicableFlag>
</item9>
<item10>
<notApplicableFlag>N</notApplicableFlag>
<certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under &amp;#167; 240.14a-11. </certifications>
</item10>
</items>
<signatureInformation>
<reportingPersonName>ForGrowth III PA B.V.</reportingPersonName>
<signatureDetails>
<signature>/s/ V. van Houten and /s/ G.J. Mulder</signature>
<title>V. van Houten and G.J. Mulder, Directors of its Director</title>
<date>01/07/2025</date>
</signatureDetails>
</signatureInformation>
<signatureInformation>
<reportingPersonName>Forbion Growth Opportunities Fund III Cooperatief U.A.</reportingPersonName>
<signatureDetails>
<signature>/s/ V. van Houten and /s/ G.J. Mulder</signature>
<title>V. van Houten and G.J. Mulder, Directors of its Director</title>
<date>01/07/2025</date>
</signatureDetails>
</signatureInformation>
<signatureInformation>
<reportingPersonName>Forbion Growth III Management B.V.</reportingPersonName>
<signatureDetails>
<signature>/s/ V. van Houten and /s/ G.J. Mulder</signature>
<title>V. van Houten and G.J. Mulder, Directors</title>
<date>01/07/2025</date>
</signatureDetails>
</signatureInformation>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
